Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies

Am J Physiol Cell Physiol. 2021 Nov 1;321(5):C779-C797. doi: 10.1152/ajpcell.00048.2021. Epub 2021 Sep 8.

Abstract

Breast cancer is the most common malignant disease in women worldwide. Early diagnosis and treatment can greatly improve the management of breast cancer. Liquid biopsies are becoming convenient detection methods for diagnosing and monitoring breast cancer due to their noninvasiveness and ability to provide real-time feedback. A range of liquid biopsy markers, including circulating tumor proteins, circulating tumor cells, and circulating tumor nucleic acids, have been implemented for breast cancer diagnosis and prognosis, with each having its own advantages and limitations. Circulating extracellular vesicles are messengers of intercellular communication that are packed with information from mother cells and are found in a wide variety of bodily fluids; thus, they are emerging as ideal candidates for liquid biopsy biomarkers. In this review, we summarize extracellular vesicle protein markers that can be potentially used for the early diagnosis and prognosis of breast cancer or determining its specific subtypes.

Keywords: biomarker; breast cancer; extracellular vesicle; liquid biopsy; protein.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy
  • Cell Line, Tumor
  • Early Detection of Cancer*
  • Extracellular Vesicles / metabolism*
  • Extracellular Vesicles / pathology
  • Female
  • Humans
  • Liquid Biopsy
  • Neoplasm Proteins / metabolism*
  • Predictive Value of Tests
  • Prognosis
  • Proteomics

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins